Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction

Conditions:   Coronary Angiography;   Glucagon-like Peptide-1
Intervention:   Diagnostic Test: plasma glucagon-like peptide-1 levels
Sponsor:   Chinese PLA General Hospital
Completed - verified April 2017

Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK)

Condition:   Blood Pressure
Intervention:   Diagnostic Test: Blood Pressure Measurement
Sponsors:   Group Health Cooperative;   Patient-Centered Outcomes Research Institute
Not yet recruiting - verified April 2017

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran Etexilate Oral Capsule;   Drug: Rivaroxaban Oral Tablet;   Drug: Edoxaban Oral Tablet;   Drug: Apixaban Oral Tablet
Sponsors:   Danish Heart Foundation;   Danish Society of Cardiology
Not yet recruiting - verified April 2017

Telemedical vs. Conventional Prehospital Care in Acute Coronary Syndromes

Condition:   Acute Coronary Syndrome
Intervention:   Procedure: Telemedical support
Sponsor:   RWTH Aachen University
Completed - verified April 2017

Optical Coherence Tomography in Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   STEMI - ST Elevation Myocardial Infarction;   NSTEMI - Non-ST Segment Elevation MI;   Atherosclerosis, Coronary
Intervention:  
Sponsors:   Charite University, Berlin, Germany;   Berlin Institut of Health (BIH), Germany
Not yet recruiting - verified April 2017

Effects of Interval Physical Training on Expiratory Flow Limitation in Recent Myocardial Infarction

Conditions:   Expiratory Flow Limitation;   Recent Myocardial Infarction
Interventions:   Other: Interval Training (IT);   Other: Inspiratory Muscle Training (IMT)
Sponsors:   Federal University of Uberlandia;   Universidade Federal de Sao Carlos
Not yet recruiting - verified April 2017

ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Intervention:   Drug: Ticagrelor
Sponsor:   Fondazione per la Ricerca Ospedale Maggiore
Not yet recruiting - verified April 2017

Ankle Brachial Index Versus Conventional Cardiac Risk Indices

Condition:   Anesthesia
Intervention:  
Sponsor:   Assiut University
Not yet recruiting - verified April 2017

Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Cardiomyopathies
Interventions:   Diagnostic Test: Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy;   Diagnostic Test: Transthoracic echocardiography;   Diagnostic Test: Computed tomography coronary artery calcium scoring;   Diagnostic Test: Cardiopulmonary exercise testing
Sponsor:   University of Leicester
Not yet recruiting - verified April 2017

Comparaison of 2 SpO2 Level Measured by Pulse Oxymetry in Complications of Acute Coronary Syndrome.

Condition:   Infarction, Myocardial
Intervention:   Device: oxygen administration
Sponsor:   Laval University
Completed - verified April 2017

No-Touch Versus Conventional Saphenous Vein Harvesting Technique

Condition:   Coronary Artery Disease
Interventions:   Procedure: No-Touch vein harvesting technique;   Procedure: Conventional vein harvesting
Sponsor:   China National Center for Cardiovascular Diseases
Not yet recruiting - verified April 2017

A Project to Improve the Diagnosis and Prognosis of Myocardial Injury Associated to Non Cardiac Surgery

Condition:   Myocardium; Injury
Interventions:   Diagnostic Test: Troponin;   Drug: Acetylsalicylic acid;   Drug: Statin
Sponsor:   Parc de Salut Mar
Not yet recruiting - verified April 2017

China Resolute Integrity 34/38 mm Study

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Intervention:   Device: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)
Sponsor:   Medtronic Vascular
Recruiting - verified April 2017

Effect of Remote Ischemic Post-conditioning on Out-of-hospital Cardiac Arrest

Condition:   Out-Of-Hospital Cardiac Arrest
Intervention:   Procedure: Remote ischemic post-conditioning
Sponsor:   Chonnam National University Hospital
Recruiting - verified April 2017

Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study

Conditions:   Ischemic Heart Disease;   Myocardial Infarction;   Inflammation
Intervention:   Drug: RiTUXimab Injection
Sponsor:   Papworth Hospital NHS Foundation Trust
Not yet recruiting - verified April 2017

Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention

Condition:   Heart Injuries
Interventions:   Drug: Dexmedetomidine;   Drug: 0.9%NaCl solution
Sponsor:   First Affiliated Hospital Xi'an Jiaotong University
Not yet recruiting - verified February 2017

Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?

Conditions:   Ischemic Heart Disease;   Coronary Heart Disease;   Myocardial Infarction
Intervention:   Behavioral: Choral Singing
Sponsors:   Nova Scotia Health Authority;   Dalhousie University
Not yet recruiting - verified April 2017

Effect of External Counter Pulsation on Ischemic Stroke

Condition:   Ischemic Stroke
Intervention:   Device: External counter pulsation (ECP)
Sponsors:   Eighth Affiliated Hospital, Sun Yat-sen University;   Shenzhen Research Institute, The Chinese University Hong Kong;   Second Affiliated Hospital of Xi'an Jiaotong University;   The Second Affiliated Hospital of Zhengzhou University
Not yet recruiting - verified April 2017

Endothelial Function in Obstructive Sleep Apnea

Condition:   Obstructive Sleep Apnea of Adult
Interventions:   Drug: Atorvastatin 10mg;   Drug: Placebo
Sponsors:   Columbia University;   National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified April 2017

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Conditions:   Type2 Diabetes;   Dyslipidemia
Interventions:   Drug: K-877;   Drug: Placebo
Sponsors:   Kowa Research Institute, Inc.;   Brigham and Women's Hospital
Recruiting - verified April 2017

RESOLUTE ONYX Post-Approval Study

Condition:   Coronary Artery Disease
Interventions:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System;   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Recruiting - verified April 2017

Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B by Women With Climacteric Syndrome

Conditions:   Climacteric Syndrome;   Menopause
Interventions:   Dietary Supplement: Amberen;   Dietary Supplement: Smart B;   Dietary Supplement: Placebo
Sponsor:   I.M. Sechenov First Moscow State Medical University
Recruiting - verified April 2017

Stanford Healthy Heart Study

Condition:   Obesity
Interventions:   Behavioral: Fun First;   Behavioral: Weight Watchers
Sponsors:   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2017

The Early Intervention and Prevention of Diabetes Foot

Condition:   Diabetes; Neuropathy, Polyneuropathy (Manifestation)
Intervention:   Device: Q-Sense_QST (TSA II)
Sponsor:   Chang Gung Memorial Hospital
Enrolling by invitation - verified May 2016

A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction

Condition:   Myocardial Infarction
Interventions:   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified April 2017

Investigating Trends in Compliance With Quality Assurance Metrics

Condition:   Postoperative Morbidity
Intervention:   Other: Receive metric feedback email
Sponsor:   University of Michigan
Completed - verified April 2017

NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH

Conditions:   Atrial Fibrillation;   Intracerebral Hemorrhage
Interventions:   Drug: NOAC;   Drug: Acetylsalicylic Acid
Sponsor:   Population Health Research Institute
Recruiting - verified April 2017

Validation of Predictors of OAC Initiation Using EMR Data

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran etexilate;   Drug: Warfarin
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2017

Cardiac Function and Microcirculation: Type 2 DIABetes and ECHOcardiographic Changes Over Time

Condition:   Left Ventricular Dysfunction
Intervention:  
Sponsor:   Svendborg Hospital
Recruiting - verified April 2017

Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization

Condition:   Peripheral Artery Disease
Intervention:   Device: REVEAL
Sponsors:   Rex Medical;   Syntactx
Not yet recruiting - verified April 2017

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Condition:   Atrial Fibrillation
Interventions:   Drug: Edoxaban-based Regimen;   Drug: VKA-based Regimen
Sponsors:   Daiichi Sankyo Inc.;   Chiltern International Inc.
Recruiting - verified April 2017

Reappraisal of Atrial Fibrillation: RACE V - Work Package 5

Condition:   Atrial Fibrillation
Intervention:   Device: Implantable loop recorder
Sponsor:   Academisch Ziekenhuis Maastricht
Recruiting - verified April 2017

Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Condition:   Node Positive HER2 Negative Breast Cancer
Interventions:   Other: Placebo;   Drug: Aspirin
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer
Recruiting - verified April 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: rhEPO;   Drug: Placebo;   Drug: Iron therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified April 2017

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Conditions:   Prostate Cancer;   Cardiovascular Disease
Interventions:   Behavioral: Nutrition;   Behavioral: Exercise;   Behavioral: Smoking cessation;   Drug: Antiplatelet agent, such as Aspirin, or other low-dose antiplatelet agent;   Drug: Statin, such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin);   Drug: ACE inhibitor
Sponsors:   McMaster University;   Prostate Cancer Canada
Recruiting - verified April 2017

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Condition:   Anaemia
Interventions:   Drug: Daprodustat;   Drug: Darbepoetin alfa;   Drug: Placebo;   Drug: Iron Therapy
Sponsor:   GlaxoSmithKline
Recruiting - verified April 2017

Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator

Conditions:   Tachycardia;   Diabetes Mellitus;   Cardiovascular Disease
Intervention:   Device: Subcutaneous Implantable Cardioverter Defibrillator
Sponsors:   Boston Scientific Corporation;   University of Rochester
Recruiting - verified April 2017

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

Condition:   Normal Physiology
Interventions:   Drug: Solu-Medrol (methylprednisolone sodium succinate);   Drug: Topical methylprenisolone 0.1%
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 15, 2017

Reduced Immunogenicity Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Condition:   Mesothelioma
Intervention:   Drug: LMB-100
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 22, 2017

WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW - ACS)

Condition:   Acute Coronary Syndrome
Intervention:   Drug: Aspirin
Sponsor:   Sheffield Teaching Hospitals NHS Foundation Trust
Completed - verified April 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2017

Perioperative Endothelial Dysfunction in Patients Undergoing Minor Abdominal Surgery

Condition:   Myocardial Injury
Intervention:   Procedure: Elective Surgery
Sponsor:   University Hospital Koge
Active, not recruiting - verified April 2017

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified April 2017

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Condition:   Carotid Artery Stenosis
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel;   Drug: Aspirin
Sponsor:   University Hospital, Basel, Switzerland
Recruiting - verified April 2017

Mobilization of Endothelial Progenitor Cells and Aspirin

Condition:   Hypertrophic Obstructive Cardiomyopathy
Intervention:   Drug: Aspirin
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified April 2017

AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions:   Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host-Disease;   Bronchiolitis Obliterans Syndrome
Intervention:   Drug: AZD9668
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified January 9, 2017

Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients

Condition:   Myocardial Infarction
Intervention:   Drug: ticagrelor
Sponsor:   Collegium Medicum w Bydgoszczy
Completed - verified April 2017

BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX

Condition:   Ischaemic Heart Disease
Interventions:   Device: Biofreedom;   Device: Orsiro
Sponsors:   Odense University Hospital;   Aarhus University Hospital Skejby;   Aalborg Universitetshospital;   Rigshospitalet, Denmark
Active, not recruiting - verified April 2017

EVOLVE Short DAPT Study

Condition:   Coronary Artery Disease
Interventions:   Drug: 3 months of dual antiplatelet therapy (DAPT);   Device: SYNERGY Stent System
Sponsor:   Boston Scientific Corporation
Recruiting - verified April 2017

National Plaque Registry and Database

Conditions:   Atherosclerosis;   Coronary Artery Disease;   Cardiovascular Disease
Intervention:  
Sponsors:   Semmelweis University Heart and Vascular Center;   Hungarian Academy of Sciences
Not yet recruiting - verified April 2017

Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics

Conditions:   Type 2 Diabetes;   Coronary Heart Disease
Interventions:   Device: TAXUS Element™ Paclitaxel-Eluting Stent System;   Device: Xience PRIME Everolimus-Eluting Stent System
Sponsors:   Fortis Escorts Heart Institute;   Boston Scientific Corporation;   Max Neeman Medical International Ltd.
Completed - verified April 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified April 2017

Contemporary Modalities in Treatment of Heart Failure

Condition:   Heart Failure
Intervention:  
Sponsor:   Silesian Centre for Heart Diseases
Recruiting - verified April 2017

Efficacy of Subintimal vs Intraluminal Approach for Atherosclerotic Chronic Occlusive Femoropopliteal Arterial Disease

Conditions:   Peripheral Arterial Disease;   Atherosclerosis
Interventions:   Procedure: Intentional intraluminal approach;   Procedure: Intentional subintimal approach
Sponsor:   Korea University Guro Hospital
Recruiting - verified April 2017

Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)

Condition:   Venous Thromboembolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified April 2017

Optilene® Suture for Coronary Artery Bypass Graft Surgery

Conditions:   Coronary Heart Disease;   Multi Vessel Coronary Artery Disease
Intervention:   Procedure: Coronary Artery Bypass Graft surgery
Sponsors:   Aesculap AG;   B.Braun Surgical SA
Recruiting - verified April 2017

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified April 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified April 2017

Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms

Condition:   Aortic Aneurysm, Abdominal
Intervention:   Device: GORE® EXCLUDER® Conformable AAA Endoprosthesis
Sponsor:   W.L.Gore & Associates
Not yet recruiting - verified April 2017

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Conditions:   Kidney Transplant;   Type 1 Diabetes
Interventions:   Drug: Alpha 1-Antitrypsin;   Procedure: Islet Transplantation;   Drug: Thymoglobulin;   Drug: Basiliximab;   Drug: Etanercept
Sponsors:   Massachusetts General Hospital;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Iowa
Recruiting - verified April 2017

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Conditions:   Chronic Ischemic Left Ventricular Dysfunction;   Myocardial Infarction
Interventions:   Drug: Autologous hMSCs;   Drug: Autologous Human C-Kit CSCs II;   Drug: Placebo;   Device: Biosense Webster MyoStar NOGA Injection Catheter System
Sponsor:   Joshua M Hare
Not yet recruiting - verified April 2017

Virtual Coronary Physiology: an Angiogram is All You Need

Condition:   Coronary Artery Disease
Intervention:   Procedure: Percutaneous Coronary Intervention
Sponsors:   Sheffield Teaching Hospitals NHS Foundation Trust;   Wellcome Trust
Completed - verified April 2017

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified April 2017

COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial

Condition:   ST Elevation Acute Myocardial Infarction
Interventions:   Drug: Exenatide;   Other: Remote Ischemic Conditioning (RIC);   Drug: Placebo
Sponsor:   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified April 2017

MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions

Condition:   Coronary Artery Disease
Intervention:   Device: MAGIC-TOUCH Drug-eluting Balloon
Sponsor:   Scitech Produtos Medicos Ltda
Recruiting - verified April 2017

Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine

Condition:   Coronary Artery Disease
Interventions:   Drug: Methylnaltrexone;   Other: Placebo;   Drug: Morphine;   Drug: Ticagrelor
Sponsor:   University of Florida
Completed - verified April 2017

Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids

Condition:   Graft-Versus-Host Disease
Intervention:   Biological: MSC
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 13, 2016

Prevention of Myocardial Injury in Non-cardiac Surgery

Conditions:   Myocardial Injury;   Myocardial Infarction
Intervention:   Procedure: Remote ischemic preconditioning
Sponsor:   University Hospital Koge
Recruiting - verified April 2017

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

Condition:   Systemic Lupus Erthematosus
Interventions:   Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified November 21, 2016

The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients

Conditions:   Cardiovascular Disease;   Acute Coronary Syndrome
Intervention:   Behavioral: Txt2Prevent
Sponsors:   Simon Fraser University;   Providence Health & Services;   University of British Columbia;   McMaster University;   Canadian Institutes of Health Research (CIHR)
Completed - verified April 2017

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified April 2017

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 9, 2016

A Study of VentriGel in Post-MI Patients

Conditions:   Myocardial Infarction;   Heart Failure;   Left Ventricular Remodeling
Intervention:   Biological: VentriGel
Sponsor:   Ventrix, Inc.
Enrolling by invitation - verified April 2017

STEEL Percutaneous Coronary Intervention

Condition:   Coronary Artery Disease
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor 60;   Drug: Ticagrelor 90
Sponsors:   Sheffield Teaching Hospitals NHS Foundation Trust;   AstraZeneca
Active, not recruiting - verified April 2017

Left Internal Thoracic Artery Bypass Versus Percutaneous Revascularization in Diabetics

Conditions:   Coronary Artery Disease;   Diabetes Mellitus
Interventions:   Procedure: Minimally Invasive Coronary Bypass;   Procedure: Percutenous Coronary Intervention
Sponsors:   Ottawa Heart Institute Research Corporation;   University of Toronto
Not yet recruiting - verified April 2017

INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events

Condition:   Ventricular Tachycardia
Interventions:   Drug: Amiodarone;   Device: Catheter Ablation
Sponsors:   Icahn School of Medicine at Mount Sinai;   Biosense Webster, Inc.
Terminated - verified April 2017

Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0

Condition:   Hypertension
Intervention:  
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Human Genome Research Institute (NHGRI)
Active, not recruiting - verified January 24, 2017

Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Conditions:   Recurrent Melanoma of the Skin;   Stage III Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified February 2017

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified April 2017

Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly

Conditions:   Non-ST-elevation Acute Coronary Syndrome;   Unstable Angina;   Non-ST-elevation Myocardial Infarction
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor or Prasugrel
Sponsors:   St. Antonius Hospital;   UMC Utrecht;   Leiden University Medical Center;   Meander Medical Center;   Medical Center Alkmaar;   Isala;   Gelre Hospitals;   Gelderse Vallei Hospital;   Medical Centre Leeuwarden;   Rijnstate Hospital
Recruiting - verified April 2017

Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation

Conditions:   Aortic Valve Disease;   Myocardial Infarction;   Stroke;   Bleeding
Interventions:   Drug: Aspirin + clopidogrel;   Drug: Aspirin monotherapy;   Drug: OAC + clopicogrel;   Drug: OAC monotherapy
Sponsor:   St. Antonius Hospital
Recruiting - verified April 2017

Early Rheumatoid Arthritis COR Intervention

Conditions:   Rheumatoid Arthritis;   Cardiovascular Diseases
Interventions:   Other: Simvastatin;   Other: Losartan;   Other: Losartan;   Other: Losartan;   Other: Metformin;   Other: Outpatient rheumatology department;   Other: Refered to general practice
Sponsor:   MD, PhD, Annemarie Lyng Svensson
Recruiting - verified April 2017

Cerebral Oxygenation in Septic Patients Using Vasopressors - the Conscious Study

Condition:   Septic Shock
Intervention:  
Sponsor:   Karl-Andre Wian
Terminated - verified April 2017

Intravascular Ultrasound Guided Drug Eluting Stents Implantation in "All-comers" Coronary Lesions (ULTIMATE Trial)

Condition:   Coronary Artery Disease
Interventions:   Procedure: Angiography;   Procedure: IVUS;   Procedure: DES implantation
Sponsor:   Nanjing First Hospital, Nanjing Medical University
Recruiting - verified April 2017

Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.

Condition:   Acute Coronary Syndrome
Interventions:   Drug: MEOPA and paracetamol;   Drug: Morphine
Sponsor:   University Hospital, Toulouse
Completed - verified April 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified April 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Active, not recruiting - verified April 2017

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Conditions:   Lung Cancer;   Breast Cancer;   Prostate Cancer;   Tumors (Others);   Ovarian Cancer
Intervention:   Biological: MVA-brachyury- TRICOM
Sponsor:   National Cancer Institute (NCI)
Completed - verified April 6, 2017

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Rivaroxaban;   Drug: Acetylsalicylic acid
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR);   Bayer;   Biotronik SE & Co. KG
Recruiting - verified April 2017

Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 22, 2016

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified April 2017

Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study

Condition:   HIV Infection
Interventions:   Drug: Aspirin 81 mg daily;   Drug: Atorvastatin 40 mg daily
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified July 29, 2016

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)

Conditions:   Hypertension;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified January 6, 2017

HEART Pathway Implementation

Conditions:   Chest Pain;   Acute Coronary Syndrome;   Chest Pain Atypical Syndrome;   Chest Pain Rule Out Myocardial Infarction
Intervention:  
Sponsors:   Wake Forest University Health Sciences;   Association of American Medical Colleges;   Donaghue Medical Research Foundation
Active, not recruiting - verified April 2017

123I-mIBG SPECT Imaging

Conditions:   Heart Failure;   Coronary Artery Disease
Intervention:   Drug: Radioisotope
Sponsors:   Ottawa Heart Institute Research Corporation;   GE Healthcare
Completed - verified April 2017

Essential Hypotension and Allostasis Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified April 2017

Resolute Integrity US Extended Length Sub-Study(RI-US XL)

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity Stent
Sponsor:   Medtronic Vascular
Active, not recruiting - verified April 2017

Effect of Lung Cancer Diagnoses on Family Behaviors

Conditions:   Lung Cancer;   Blood Relatives of Patient w/Lung Cancer;   Cigarette Smokers
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed - verified February 25, 2016

Using a Personal Heart Rhythm Monitor to Diagnose Paroxsymal Atrial Fibrillation in the Community

Conditions:   Paroxysmal Atrial Fibrillation;   Stroke
Interventions:   Device: Automated Cardiac Event Recorder;   Device: Personal Heart Rhythm Monitor
Sponsors:   University of Surrey;   Royal Surrey County Hospital NHS Foundation Trust
Completed - verified April 2017

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Conditions:   MDS (Myelodysplastic Syndrome);   Myeloproliferative Disorder;   Lymphoma, Non-Hodgkin;   ALL (Acute B-Lymphoblastic Leukemia);   AML (Acute Meylogenous Leukemia
Intervention:   Device: Graft Manipulation (CD34+ Selection)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Children's Research Institute
Recruiting - verified April 6, 2017

Antibody Treatment for Advanced Celiac Disease

Conditions:   Celiac Disease;   Celiac Sprue;   Gluten Enteropathy;   Gluten-Sensitive Enteropathy
Intervention:   Biological: Hu-Mik- Beta-1
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic
Recruiting - verified March 2, 2017

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention &Amp; Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute;   Janssen Research & Development, LLC
Active, not recruiting - verified April 2017

Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Biological: 12.5 M Mesenchymal Precursor Cells (MPC);   Other: Placebo;   Biological: 25M Mesenchymal Precursor Cells (MPC)
Sponsor:   Mesoblast, Ltd.
Active, not recruiting - verified September 2016

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

Conditions:   ST Segment Elevation Myocardial Infarction (STEMI);   Allogeneic Mesenchymal Bone Marrow Cells
Intervention:   Biological: Stem cells
Sponsors:   Stemedica Cell Technologies, Inc.;   CardioCell LLC
Withdrawn - verified April 2017

Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Device: STENTYS self-apposing stent;   Device: VISION balloon-expandable stent
Sponsor:   Stentys
Terminated - verified November 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2017

Evaluating New Radiation Techniques for Cardiovascular Imaging

Condition:   Coronary Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 23, 2017

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Conditions:   Myeldysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia;   Bone Marrow Diseases;   Neutropenia;   Acute Myeloid Leukemia (AML)
Interventions:   Drug: Clofarabine;   Drug: Lenalidomide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Celgene Corporation
Completed - verified February 13, 2017

Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia

Conditions:   Aplastic Anemia;   Neutropenia;   Pancytopenia;   Anemia;   Thrombocytopenia
Interventions:   Drug: Eltrombopag;   Drug: Horse Anti-Thymocyte Globulin (ATG);   Drug: Cyclosporine A (CSA)
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 7, 2017

Imaging Study of the Lungs During an Allergic Asthma Attack

Conditions:   Asthma;   Atopy
Interventions:   Biological: Standardized Cat Allergen Extract and Standardized Dust Mite Allergen;   Radiation: Computed Tomography imaging, functional Positron Emission Tomography imaging;   Drug: Nebulized methacholine inhalation
Sponsors:   Massachusetts General Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2017

Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI

Conditions:   Myocardial Infarction;   Cardiovascular Disease
Interventions:   Other: 6 months DAPT;   Other: 12 months DAPT
Sponsors:   Maasstad Hospital;   Medtronic
Active, not recruiting - verified April 2017

Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)

Condition:   Coronary Artery Disease
Interventions:   Procedure: Filtrap™ + Thrombus aspiration catheter;   Procedure: Thrombus aspiration catheter
Sponsors:   Yokohama City University Medical Center;   Teikyo University
Completed - verified April 2017

Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Condition:   Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
Sponsors:   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
Recruiting - verified April 2017

Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.

Conditions:   Myocardial Infarction;   Multivessel Coronary Artery Disease
Interventions:   Procedure: FFR-guided revascularisation strategy;   Procedure: randomised to guidelines group
Sponsors:   Maasstad Hospital;   Abbott Vascular;   St. Jude Medical
Active, not recruiting - verified April 2017

Femoral Versus Radial Access for Primary PCI

Conditions:   Myocardial Infarction;   STEMI
Intervention:   Procedure: Primary Percutaneous Coronary Intervention (PPCI)
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified April 2017

New Heart Imaging Techniques to Evaluate Possible Heart Disease

Conditions:   Healthy;   Obesity;   Diabetes;   Arteriosclerosis;   Healthy Volunteers
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 28, 2017

Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock

Condition:   Cardiogenic Shock
Interventions:   Drug: epinephrine perfusion;   Drug: norepinephrine perfusion
Sponsor:   Central Hospital, Nancy, France
Completed - verified April 2017

The Natural History of Graft-Versus-Host Disease in the Eyes

Condition:   Graft-Versus-Host Disease
Intervention:  
Sponsor:   National Eye Institute (NEI)
Completed - verified February 5, 2016

Continuous Positive Airway Pressure (CPAP) in Patients With Acute Coronary Syndrome and Obstructive Sleep Apnea (OSA)

Conditions:   Acute Coronary Syndrome;   Obstructive Sleep Apnea
Interventions:   Other: Standard care;   Device: continuous positive airway pressure
Sponsors:   Sociedad Española de Neumología y Cirugía Torácica;   ResMed;   Fondo de Investigacion Sanitaria;   EsteveTeijin Healthcare;   Societat Catalana de Cardiologia;   Sociedad Madrileña de Neumologia
Recruiting - verified April 2016

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition:   Atherosclerosis
Interventions:   Drug: Canakinumab;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting - verified April 2017

RESOLUTE China RCT

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Interventions:   Device: Taxus Liberte Paclitaxel-Eluting Coronary Stent System;   Device: Resolute Zotarolimus-Eluting Coronary Stent System
Sponsor:   Medtronic Vascular
Active, not recruiting - verified April 2017

Efficacy and Safety of Adjunctive Cilostazol in Acute Myocardial Infarction Patients

Condition:   Acute Myocardial Infarction
Intervention:   Drug: antiplatelet therapy
Sponsor:   Korea University Guro Hospital
Recruiting - verified April 2017

Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

Conditions:   Bronchiolitis Obliterans;   Graft vs Host Disease
Intervention:   Drug: Cyclosporine Inhalation Solution
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 6, 2017

RESOLUTE China Registry:

Conditions:   Ischemic Heart Disease;   Stenotic Coronary Lesion;   Cardiovascular Diseases;   Arteriosclerosis;   Coronary Artery Disease
Intervention:  
Sponsor:   Medtronic Vascular
Active, not recruiting - verified April 2017

Study to Monitor the Effects of Androgen Suppression Treatment on the Heart

Condition:   Prostate Cancer
Intervention:   Radiation: PET scan and ultrasound
Sponsor:   Ottawa Heart Institute Research Corporation
Completed - verified April 2017

Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis

Conditions:   Hypertrophic Cardiomyopathy;   Acute Coronary Syndrome
Intervention:   Radiation: 99mTc-NC100692
Sponsor:   Ottawa Heart Institute Research Corporation
Terminated - verified April 2017

Complete Lesion Versus Culprit Lesion Revascularization

Condition:   Myocardial Infarction
Interventions:   Procedure: complete revascularization;   Procedure: Culprit revasularization
Sponsor:   Korea University Guro Hospital
Available - verified April 2017

Cardiac MRI for Patients Enrolled in INFUSE-AMI

Conditions:   Acute Myocardial Infarction;   Coronary Artery Disease;   Myocardial Fibrosis;   Gadolinium;   Myocardial Edema
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified October 11, 2012

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Completed - verified April 2017

Comparison of Cardiac Computed Tomography and Vasodilator Stress Magnetic Resonance Imaging Perfusion in Patients With Prior Equivocal Stress Test for Detection of Coronary Artery Disease

Conditions:   Myocardial Ischemia;   Coronary Artery Disease;   Myocardial Infarction
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified January 31, 2017

Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

Conditions:   Renal Cancer;   Kidney Cancer
Interventions:   Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
Sponsor:   National Cancer Institute (NCI)
Terminated - verified August 24, 2012

30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event

Conditions:   Stroke;   Transient Ischemic Attack;   Atrial Fibrillation;   Atrial Flutter
Interventions:   Device: a 30-day ambulatory cardiac event monitor;   Device: 24-hour Holter
Sponsor:   Sunnybrook Health Sciences Centre
Active, not recruiting - verified April 2017

GORE® HELEX® Septal Occluder / GORE® Septal Occluder for Patent Foramen Ovale (PFO) Closure in Stroke Patients - The Gore REDUCE Clinical Study

Conditions:   Stroke;   Transient Ischemic Attack
Interventions:   Device: GORE® HELEX® Septal Occluder / GORE® Septal Occluder;   Other: Antiplatelet Medical Therapy
Sponsor:   W.L.Gore & Associates
Active, not recruiting - verified April 2017

Natural Killer Cells and Bortezomib to Treat Cancer

Conditions:   Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention:   Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 13, 2017

Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease

Conditions:   Sclerotic Graft Versus Host Disease;   Imatinib Mesylate
Intervention:   Drug: Gleevec, STI571(Imatinib Mesylate)
Sponsor:   National Cancer Institute (NCI)
Completed - verified April 2017

Hepatitis C Treatment and Atherosclerosis

Conditions:   Chronic Hepatitis C;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 24, 2015

Biomarkers in Exhaled Breath From Asthmatic Patients

Condition:   Asthma
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Terminated - verified November 28, 2012

Insulin Resistance and Atherosclerosis in Women With Lupus

Conditions:   Systemic Lupus Erythematosus;   Insulin Resistance;   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Completed - verified April 29, 2016

The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol

Condition:   Sitosterolemia
Intervention:   Behavioral: High/Low Sitosterol
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified May 24, 2016

Effect of Diet on Vascular Disease in Pre-Menopausal Women

Conditions:   Cardiovascular Diseases;   Vascular Disease;   Inflammation;   Insulin;   Triglycerides
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified February 14, 2017

Cardiovascular Disease Screening

Conditions:   Congenital Heart Disease;   Atherosclerosis;   Myocardial Ischemia;   Myocardial Infarction;   Acquired Heart Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 27, 2016

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

Condition:   Graft vs Host Disease
Interventions:   Drug: Topical Dexamethasone;   Drug: Placebo
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 4, 2017

Genetic Factors in Atherosclerosis

Condition:   Atherosclerosis
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Completed - verified March 21, 2013

Identification of Genes Expressed in Atherosclerotic Plaque

Condition:   Atherosclerosis
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 3, 2016

Causes and Natural History of Dyslipidemias

Condition:   Dyslipidemias
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 27, 2017

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Conditions:   Immunosuppression;   Leukemia
Intervention:   Device: SOLEX 300i Stem Cell Selection
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 21, 2016

E-Selectin Nasal Instillation to Prevent Secondary Stroke

Conditions:   Ischemic Attack, Transient;   Transient
Intervention:   Drug: Intransal instillation of E-selectin
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified March 23, 2017

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Procedure: PBSC transplantation;   Genetic: T cell DLI with sirolimus generated donor TH-2 cells;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim;   Genetic: T-Rapa cell DLI
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified February 3, 2017

Integrated Biomarker And Imaging Study - 2

Condition:   Atherosclerosis
Interventions:   Drug: SB-480848;   Drug: SB-480848 matching placebo
Sponsor:   GlaxoSmithKline
Completed - verified April 2017

Body Weight Regulation in Patients With Narcolepsy

Condition:   Narcolepsy
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified June 19, 2013

Heart Muscle Viability and Remodeling in Individuals Post-Heart Attack

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Myocardial Infarction;   Heart Diseases;   Heart Failure, Congestive
Intervention:  
Sponsors:   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2017

Subclinical Thyroid Dysfunction and Risk of Myocardial Infarction and Stroke

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Hypothyroidism;   Myocardial Infarction;   Cerebrovascular Accident
Intervention:  
Sponsors:   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified December 2015

Genetic Causes of Panic Disorder

Condition:   Panic Disorder
Intervention:  
Sponsor:   National Institute of Mental Health (NIMH)
Completed - verified July 1, 2016

Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Drug: Th2/Tc2 Cells
Sponsor:   National Cancer Institute (NCI)
Completed - verified August 9, 2013

Dietary Fatty Acids, PPAR Activated Genes, and CHD

Conditions:   Coronary Disease;   Cardiovascular Diseases;   Heart Diseases;   Myocardial Infarction
Intervention:  
Sponsors:   Harvard School of Public Health;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified April 2017

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Condition:   Hematologic Neoplasms
Intervention:   Procedure: Stem cell transplantation
Sponsor:   National Cancer Institute (NCI)
Completed - verified September 25, 2014

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Conditions:   Mycosis Fungoides;   Sezary Syndrome
Intervention:   Drug: Campath-1H
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting - verified March 31, 2017

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified March 9, 2017

Natural History of Stroke: Cause and Development

Conditions:   Nervous System Disease;   Transient Ischemic Attack;   Neurologic Disorders;   Stroke;   Vascular Disease
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 5, 2016

Diagnosis of Pheochromocytoma

Condition:   Pheochromocytoma
Intervention:  
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 17, 2017

Evaluation of Lipoproteins

Conditions:   Hyperlipidemia;   Hyperlipoproteinemia;   Hypolipoproteinemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 23, 2017

Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers

Conditions:   Atherosclerosis;   Hypercholesterolemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 22, 2017

Comparing Therapies for the Treatment of Severe Aplastic Anemia

Conditions:   Aplastic Anemia;   Hematologic Disease
Interventions:   Drug: Antithymocyte globulin & Cyclosporin A;   Drug: Cyclophosphamide & Cyclosporin A
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified October 11, 2016

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Conditions:   Graft vs Host Disease;   Healthy;   Lymphopenia
Intervention:   Drug: G-CSF
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   New York University and New York Genome Center
Recruiting - verified April 17, 2017

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

Conditions:   Graft vs Host Disease;   Hematologic Neoplasm;   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Procedure: Allogeneic Bone Marrow Transplant
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 18, 2016